HK1144556A1 - Inhibition of tumor metastasis by anti-neuropilin antibodies - Google Patents

Inhibition of tumor metastasis by anti-neuropilin antibodies

Info

Publication number
HK1144556A1
HK1144556A1 HK10111154.7A HK10111154A HK1144556A1 HK 1144556 A1 HK1144556 A1 HK 1144556A1 HK 10111154 A HK10111154 A HK 10111154A HK 1144556 A1 HK1144556 A1 HK 1144556A1
Authority
HK
Hong Kong
Prior art keywords
inhibition
tumor metastasis
neuropilin
antibodies
neuropilin antibodies
Prior art date
Application number
HK10111154.7A
Other languages
English (en)
Chinese (zh)
Inventor
Yan Wu
Wei-Ching Liang
Ryan Jefferson Watts
Anil Durgadas Bagri
Original Assignee
健泰科生物技術公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 健泰科生物技術公司 filed Critical 健泰科生物技術公司
Publication of HK1144556A1 publication Critical patent/HK1144556A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10111154.7A 2007-05-17 2010-11-30 Inhibition of tumor metastasis by anti-neuropilin antibodies HK1144556A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/069179 WO2008143665A1 (en) 2007-05-17 2007-05-17 Inhibition of tumor metastasis by anti neuropilin 2 antibodies

Publications (1)

Publication Number Publication Date
HK1144556A1 true HK1144556A1 (en) 2011-02-25

Family

ID=39301228

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10102110.9A HK1134040A1 (en) 2007-05-17 2010-03-01 Inhibition of tumor metastasis by anti neuropilin 2 antibodies
HK10111154.7A HK1144556A1 (en) 2007-05-17 2010-11-30 Inhibition of tumor metastasis by anti-neuropilin antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10102110.9A HK1134040A1 (en) 2007-05-17 2010-03-01 Inhibition of tumor metastasis by anti neuropilin 2 antibodies

Country Status (17)

Country Link
US (2) US8648173B2 (xx)
EP (1) EP2152307B1 (xx)
JP (1) JP5745840B2 (xx)
KR (1) KR101520115B1 (xx)
CN (1) CN101754771B (xx)
AU (1) AU2007353778B9 (xx)
BR (1) BRPI0721660A2 (xx)
CA (1) CA2687247A1 (xx)
CR (1) CR11126A (xx)
ES (1) ES2469743T3 (xx)
HK (2) HK1134040A1 (xx)
IL (1) IL202005A (xx)
MA (1) MA31435B1 (xx)
MX (1) MX2009012421A (xx)
NO (1) NO20093542L (xx)
UA (1) UA99292C2 (xx)
WO (1) WO2008143665A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141275A1 (en) * 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
CN102667484A (zh) * 2009-10-13 2012-09-12 约翰·霍普金斯大学 识别黑素瘤肿瘤细胞的生物标记
DK3460054T3 (da) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
WO2015095686A1 (en) 2013-12-20 2015-06-25 Trustees Of Boston University Assays and methods relating to the treatment of melanoma
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
JP2020522562A (ja) * 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
CN113226367A (zh) * 2018-04-06 2021-08-06 Atyr 医药公司 包括抗nrp2抗体的组合物和方法
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
CN114277152A (zh) * 2022-01-14 2022-04-05 张赟建 用于预测甲状腺乳头状癌淋巴结转移的特异性基因及制备方法
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
DK1695985T3 (da) 1997-04-07 2011-06-14 Genentech Inc Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese
JP4404479B2 (ja) 1997-12-09 2010-01-27 チルドレンズ・メディカル・センター・コーポレイション 血管内皮増殖因子の可溶性インヒビターおよびその使用
EP1037925A2 (en) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Antagonists of neuropilin receptor functional and use thereof
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20080057028A1 (en) 2002-10-02 2008-03-06 Institute Nationale De La Sante Et De La Recherche Medicale (Inserm) Vegf-C or Vegf-D Materials and Methods for Stimulation of Neural Stem cells
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
UA96139C2 (xx) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)$антитело к нейропилину-1 (nrp1)

Also Published As

Publication number Publication date
NO20093542L (no) 2010-02-12
ES2469743T3 (es) 2014-06-18
HK1134040A1 (en) 2010-04-16
AU2007353778B9 (en) 2014-04-03
MX2009012421A (es) 2009-12-01
US8920805B2 (en) 2014-12-30
UA99292C2 (uk) 2012-08-10
JP5745840B2 (ja) 2015-07-08
MA31435B1 (fr) 2010-06-01
KR20100018567A (ko) 2010-02-17
AU2007353778A1 (en) 2008-11-27
CN101754771B (zh) 2015-03-04
CA2687247A1 (en) 2008-11-27
IL202005A (en) 2014-11-30
CR11126A (es) 2010-05-19
JP2010527350A (ja) 2010-08-12
US8648173B2 (en) 2014-02-11
EP2152307B1 (en) 2014-04-16
US20100172921A1 (en) 2010-07-08
BRPI0721660A2 (pt) 2013-01-22
IL202005A0 (en) 2010-06-16
CN101754771A (zh) 2010-06-23
AU2007353778B2 (en) 2013-11-07
EP2152307A1 (en) 2010-02-17
WO2008143665A1 (en) 2008-11-27
KR101520115B1 (ko) 2015-05-13
US20140234312A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
HK1144556A1 (en) Inhibition of tumor metastasis by anti-neuropilin antibodies
ZA201201107B (en) Cancer metastasis inhibitor
IL229512A0 (en) Anti-vegf antibodies
IL217796A0 (en) Inhibition of tumor metastasis using bv8-or g-csf-antagonists
EP2121008A4 (en) USES OF MONOCLONAL ANTIBODY 8H9
HK1142095A1 (zh) 使用抗衰老化合物產生蛋白質的方法
ZA201005348B (en) Humanized anti-c5ar antibodies
SI2200700T1 (sl) Nova protitelesa
IL200919A0 (en) Methods for generation of antibodies
HRP20180485T1 (hr) Monoklonska antitijela za gt468 za liječenje raka
EP2331134A4 (en) ANTI-PANCREAS CANCER ANTIBODY
EP2648754A4 (en) METHODS OF INHIBITING THE METASTASIS OF CANCER
HK1142128A1 (en) Methods of prognosis
GB0702854D0 (en) Method for the synthesis of sucrose-6-esters
GB0702888D0 (en) Novel Antibodies
IL225689A0 (en) Cancer treatment/inhibition of metastasis
ZA201100123B (en) Bromine-facilitated synthesis of fluoro-sulfur compounds
ZA201003729B (en) Conjugates of anti-rg-1 antibodies
EP2217247A4 (en) NEW SYNTHESIS OF BETA NUCLEOSIDES
GB2459413B (en) Methods for the synthesis of perfluoroparacyclophane
EP2155241A4 (en) PREVENTION OF CANCER BY IMMUNIZING
AU2007900591A0 (en) Inhibition of Metastasis
AU2008906309A0 (en) Inhibition of antibody production
PL384700A1 (pl) Sposób syntezy 1-propenyloksyalkoholu
FI20061046A0 (fi) Syövän etäispesäkkeiden estäminen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190521